Ketamine in the treatment of cocaine use disorders
DOI:
https://doi.org/10.5902/2179460X44077Keywords:
Cocaine treatment, Ketamine, Motivation, URICA, EAS-40Abstract
Introduction: ketamine is a dissociative anesthetic and, recently, its antidepressant properties has been described. Besides, its safety has been proven in the treatment of Stimulant Use Disorders. Objective: to evaluate the use of ketamine in the treatment of Stimulant Use Disorders (specially cocaine and its byproducts). Methods: patient's motivation for change was measured by URICA scale and psychiatric symptoms by EAS-40 score, both before and after the intervention. Results: it was verified, after the comparison between the Readiness Score means, an increase in the motivation for change after ketamine’s single administration, when compared to the moments before and after the intervention. Analyzing the Global Severity Index before and after ketamine administration, by EAS-40 score, we noticed a slight reduction of the psychiatric symptoms before and after the intervention. Conclusion: it was proven that ketamine's single administration led to a quick and lasting improvement on the user's motivation without worsening the mental health status.
Downloads
References
ABDALLA, Renata Rigacci et al. Prevalence of Cocaine Use in Brazil: Data from the II Brazilian National Alcohol and Drugs Survey (BNADS). Addictive Behaviors, 2014.
AMERICAN PSYCHIATRIC ASSOCIATION. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. American Psychiatric Association, 2013.
ANDRADE, Chittaranjan (2004). Ketamine for depression, 4: In what dose, at what rate, by what route, for how long, and at what frequency? Journal of Clinical Psychiatry, 2017.
BANDEIRA, Marina de Bittencourt et al. Patients' perception of treatment in mental health services: validation of the Perceived Change Scale. Psychology: Reflection and Criticism, v. 24, n. 2, p. 236–244, 2011.
BASTOS, Francis I; BERTONI, Neilane (2004). National Research on crack use: who are crack users and/or similar in Brazil? How many are in Brazilian capitals? Rio de Janeiro: ICICT, 2014.
BERMAN, R. M., CAPIELLO, A., ANAND,A., et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351–354, 2000
CASTRO, Marcelle M Lobo Dinis; PASSOS, Sonia Regina Lambert. Motivational interview and motivation scales for treatment in drug dependence. Rev. psiquiatr. clín., vol.32, n.6, pp.330-335, 2005
CROSS, Alan J.; ANTHENELLI, Robert (2009). LI, Xia. Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction. Biological Psychiatry, 2018.
DAKWAR, E. et al. (2009). A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology, 2018.
DAKWAR, E et al. Cocaine self-administration disrupted by the N-methyl-D-aspartate ketamine antagonist receptor: a randomized, crossover trial. Molecular psychiatry, 2016.
DAKWAR, Elias et al. The effects of sub ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biological Psychiatry, v. 76, n. 1, p. 40–46, 2014.
DE LAAT, Bart et al. Glutamatergic Biomarkers for Cocaine Addiction: A Longitudinal Study Using MR Spectroscopy and mGluR5 PET in Self-Administering Rats. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
DUNN DP, BASTACKY JMR, GRAY CC, ABTAHI S, PJ CURRIE. Role of mesolimbic ghrelin in the acquisition of cocaine reward. Neurosci Lett. 2019 Sep 14;709:134367.
FIELD, C. A., ADINOFF, B., HARRIS, T. R., BALL, S. A., CARROL, K. M. Construct, concurrent and predictive validity of the URICA: Data from two multi-site clinical trials. Drug and Alcohol Dependence, 101(1-2), 115–123, 2009.
GIGLIOTTI A, MALBERGIER A, MARQUES ACPR, MARQUES R, Araújo MR; ANDRADA NC, LARANJEIRA R, BUZZINI RF, Bernardo WM. Cocaine Abuse and Dependence. Brazilian Psychiatric Association - Guidelines Project, 2016.
GLOBAL SURVEY 2017. 2017. Available at: https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2017_key-findings-report_final.pdf . Accessed Apr. 19, 2018.
GUIDELINES, Project. Project Guidelines Abuse and Dependency: Crack Project Guidelines. Interfaces, p. 1–31, 2011.
INTERNATIONAL MEDICAL PRODUCTS PRICE GUIDE. 2018. Available at: http://mshpriceguide.org/en/single-drug-information/?DMFId=454&searchYear=2015 . Accessed Apr. 19, 2018.
IVAN EZQUERRA-ROMANO, I et al. Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology, 2018.
KOLP, Eli et al. Entheogen-enhanced transpersonal psychotherapy of addictions: Focus on clinical applications of ketamine for treating alcoholism. The Praeger international collection on addictions, Vol 3: Characteristics and treatment perspectives., 2009.
KRUPITSKY, Evgeny et al. Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. Journal of Substance Abuse Treatment, 2002.
KRUPITSKY, M Evgeny.; GRINENKO, AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. Psychoactive Drugs, Apr-Jun;29(2):165-83, 1997.
LALONI, Diana Tosello (2004). Symptom assessment scale - 90-R-SCL-90-R: adaptation, accuracy and validity. Campinas; s.n; 2001. 214 p.
LI, Xia et al. Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. Neuropharmacology, 2014.
LOO, C. K. et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 2016.
PERRY, Edward B. et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology, 2007.
PROCHASKA, J. O.; DiCLEMENTE, C.C.; NORCROSS, J.C. In search of how people change: applications to addictive behavior. American Psychologist, Washington, v. 47, p. 1102-1114, 1992.
PROCHASKA, J., et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychology, 13, 39-46, 1994.
REZVANI, Amir H. et al. Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats. Neuroscience Letters, 2018.
SCHMIDT, D. Heath; PIERCE, Christopher R. Cocaine-induced neuroadaptations in glutamate transmission: Potential therapeutic targets for craving and addiction. Annals of the New York Academy of Sciences. 2010
SZUPSZYNSKI, Karen Priscilla Del Rio; OLIVEIRA, Margareth da Silva. Brazilian adaptation of the University of Rhode Island Change Assessment (URICA) for illicit substances. Psycho-USF, 2008.
UYS, Joachim (2009). LALUMIERE, Ryan (2004). Glutamate: The New Frontier in Pharmacotherapy for Cocaine Addiction. CNS & Neurological Disorders - Drug Targets, 2008.
WHO, WHO, WHO, WHO, 19th WHO Model List of Essential Medicines. WHO, WHO, WHO, WHO, 2015.
ZANOS, Panos et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 2016.
Published
Versions
- 2022-04-06 (2)
- 2021-05-18 (1)
How to Cite
Issue
Section
License
To access the DECLARATION AND TRANSFER OF COPYRIGHT AUTHOR’S DECLARATION AND COPYRIGHT LICENSE click here.
Ethical Guidelines for Journal Publication
The Ciência e Natura journal is committed to ensuring ethics in publication and quality of articles.
Conformance to standards of ethical behavior is therefore expected of all parties involved: Authors, Editors, Reviewers, and the Publisher.
In particular,
Authors: Authors should present an objective discussion of the significance of research work as well as sufficient detail and references to permit others to replicate the experiments. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable. Review Articles should also be objective, comprehensive, and accurate accounts of the state of the art. The Authors should ensure that their work is entirely original works, and if the work and/or words of others have been used, this has been appropriately acknowledged. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. Authors should not submit articles describing essentially the same research to more than one journal. The corresponding Author should ensure that there is a full consensus of all Co-authors in approving the final version of the paper and its submission for publication.
Editors: Editors should evaluate manuscripts exclusively on the basis of their academic merit. An Editor must not use unpublished information in the editor's own research without the express written consent of the Author. Editors should take reasonable responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper.
Reviewers: Any manuscripts received for review must be treated as confidential documents. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should be conducted objectively, and observations should be formulated clearly with supporting arguments, so that Authors can use them for improving the paper. Any selected Reviewer who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the Editor and excuse himself from the review process. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
